Search

To document the viral zoonotic risks in Vietnam, fecal samples were systematically collected from a number of mammals in southern Vietnam and subjected to agnostic deep sequencing. We describe here novel Vietnamese bunyavirus sequences detected in bat feces. The complete L and S segments from 14 viruses were determined.

This paper demonstrates the concept of applying learning curves in a consistent manner to performance as well as cost variables in order to assess the future development of power plants with CO2 capture. An existing model developed at Carnegie Mellon University, which had provided insight into the potential learning of cost variables in power plants with CO2 capture, is extended with learning curves for several key performance variables, including the overall energy loss in power plants, the energy required for CO2 capture, the CO2 capture ratio (removal efficiency), and the power plant availability. Next, learning rates for both performance and cost parameters were combined with global capacity projections for fossil-fired power plants to estimate future cost and performance of these power plants with and without CO2 capture. The results of global learning are explicitly reported, so that they can be used for other purposes such as in regional bottom-up models. Results of this study show that IGCC with CO2 capture has the largest learning potential, with significant improvements in efficiency and reductions in cost between 2001 and 2050 under the condition that around 3100 GW of combined cycle capacity is installed worldwide. Furthermore, in a scenario with a strict climate policy, mitigation costs in 2030 are 26, 11, 19 €/t (excluding CO2 transport and storage costs) for NGCC, IGCC, and PC power plants with CO2 capture, respectively, compared to 42, 13, and 32 €/t in a scenario with a limited climate policy. Additional results are presented for IGCC, PC, and NGCC plants with and without CO2 capture, and a sensitivity analysis is employed to show the impacts of alternative assumptions on projected learning rates of different systems.

This paper demonstrates the concept of applying learning curves in a consistent manner to performance as well as cost variables in order to assess the future development of power plants with CO2 capture. An existing model developed at Carnegie Mellon University, which had provided insight into the potential learning of cost variables in power plants with CO2 capture, is extended with learning curves for several key performance variables, including the overall energy loss in power plants, the energy required for CO2 capture, the CO2 capture ratio (removal efficiency), and the power plant availability. Next, learning rates for both performance and cost parameters were combined with global capacity projections for fossil-fired power plants to estimate future cost and performance of these power plants with and without CO2 capture. The results of global learning are explicitly reported, so that they can be used for other purposes such as in regional bottom-up models. Results of this study show that IGCC with CO2 capture has the largest learning potential, with significant improvements in efficiency and reductions in cost between 2001 and 2050 under the condition that around 3100 GW of combined cycle capacity is installed worldwide. Furthermore, in a scenario with a strict climate policy, mitigation costs in 2030 are 26, 11, 19 €/t (excluding CO2 transport and storage costs) for NGCC, IGCC, and PC power plants with CO2 capture, respectively, compared to 42, 13, and 32 €/t in a scenario with a limited climate policy. Additional results are presented for IGCC, PC, and NGCC plants with and without CO2 capture, and a sensitivity analysis is employed to show the impacts of alternative assumptions on projected learning rates of different systems.

A 2-yr-old boy who had undergone orthotopic liver transplantation for biliary atresia 6 months prior presented with generalized lymphadenopathy. Physical exam revealed lymphadenopathy only; the patient had no gastrointestinal signs or symptoms. CT was used to evaluate the patient's lymphadenopathy. The findings were consistent with PTLD, and an incidental intussusception causing small bowel obstruction was found. The intussusception was successfully managed expectantly, and the patient's PTLD responded to administration of rituximab. The etiology, diagnosis and management of intussusception is discussed.

Internal jugular thrombophlebitis usually results from contiguous infection or central catheterization. Ultrasonography and CT allow rapid, noninvasive methods of confirming the diagnosis of this condition. Although the choice of modality has not been systematically examined, where local expertise exists for both, ultrasonography is less expensive and should provide adequate images.

Several aspects of the disparity in birth ratio of males over females are discussed including variations among different races variations by order of birth by age of the parent and in multiple births. Avenues of statistical exploration are suggested in an attempt to indicate certain peculiarities in nature. The Negro population in the United States has a sex ratio of 102 males to 100 females as opposed to 105:100 for whites a highly significant difference. Inferences from these statistics are suggested for study of the sex ratios of mixed unions. The group classified as Mulatto show a lower sex ratio and further analysis of this was suggested including examination of slave records. For the white population sex ratio declines from 106.2 to 102.9 between 1st order and 7th order births. This is highly significant. However nonwhite determinations were more irregular. Data limitations on sex ratio by age of parent prevented conclusive results. Multiple births among whites show a decline from 105.3 for single live births to 103.2 for twins and 86.1 for all other plural deliveries. Among nonwhites these ratios are 102.3 99.7 and 102.6 respectively. Further information should be developed using the multiple facts relating to the sex ratio at birth.

Aurora kinase overexpression has been observed in patients with hematologic malignancies. MK-0457, a pan-aurora kinase inhibitor that also inhibits the ABL T315I mutant, was evaluated to treat patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome (Ph+) acute lymphoblastic leukemia (ALL) with the T315I mutation. Adults with Ph+ chronic phase (CP)-, accelerated phase (AP)- or blast phase (BP)-CML, or ALL and documented BCR-ABL T315I mutation were treated with a 5-day continuous infusion of MK-0457 administered every 14 days at 40 mg/m(2)/h, 32 mg/m(2)/h or 24 mg/m(2)/h. Fifty-two patients (CP, n=15; AP, n=14; BP, n=11; Ph+ ALL, n=12) were treated. Overall, 8% of patients achieved major cytogenetic response; 6% achieved unconfirmed complete or partial response; 39% had no response. Two patients (CP CML) achieved complete hematologic response. No patients with advanced CML or Ph+ ALL achieved major hematologic response. The most common adverse event (AE) was neutropenia (50%). The most common grade 3/4 AEs were neutropenia (46%) and febrile neutropenia (35%). MK-0457 demonstrated minimal efficacy and only at higher, intolerable doses; lower doses were tolerated and no unexpected toxicities were observed. These data will assist in the development of future aurora kinase inhibitors and in the selection of appropriate target patient populations.